Identification/NN
and/CC
Functional/JJ
Characterization/NN
of/IN
P159L/NN
Mutation/NN
in/IN
HNF1B/NN
in/IN
a/DT
Family/JJ
with/IN
Maturity-Onset/NN
Diabetes/NNS
of/IN
the/DT
Young/NN
5/CD
(/(
MODY5/NN
)/)
./.
====================
Mutation/NN
in/IN
HNF1B/NN
,/,
the/DT
hepatocyte/NN
nuclear/JJ
factor-1β/NN
(/(
HNF-1β/NN
)/)
gene/NN
,/,
results/VBZ
in/IN
maturity-onset/NN
diabetes/NNS
of/IN
the/DT
young/JJ
(/(
MODY/NN
)/)
5/CD
,/,
which/WDT
is/VBZ
characterized/VBN
by/IN
gradual/JJ
impairment/NN
of/IN
insulin/NN
secretion/NN
./.
====================
However/RB
,/,
the/DT
functional/JJ
role/NN
of/IN
HNF-1β/NN
in/IN
insulin/NN
secretion/NN
and/CC
glucose/NN
metabolism/NN
is/VBZ
not/RB
fully/RB
understood/VBN
./.
====================
We/PRP
identified/VBD
a/DT
family/NN
with/IN
early-onset/JJ
diabetes/NNS
that/DT
fulfilled/JJ
the/DT
criteria/NNS
of/IN
MODY/NN
./.
====================
Sanger/RBR
sequencing/NN
revealed/VBD
that/IN
a/DT
heterozygous/JJ
P159L/NN
(/(
CCT/NN
to/TO
CTT/NN
in/IN
codon/NN
159/CD
in/IN
the/DT
DNA-binding/JJ
domain/NN
)/)
mutation/NN
in/IN
HNF1B/NN
was/VBD
segregated/VBN
according/VBG
to/TO
the/DT
affected/VBN
status/NN
./.
====================
To/TO
investigate/VB
the/DT
functional/JJ
consequences/NNS
of/IN
this/DT
HNF1B/NN
mutation/NN
,/,
we/PRP
generated/VBD
a/DT
P159L/NN
HNF1B/NN
construct/NN
./.
====================
The/DT
wild-type/JJ
and/CC
mutant/JJ
HNF1B/NN
constructs/NNS
were/VBD
transfected/VBN
into/IN
COS-7/NN
cells/NNS
in/IN
the/DT
presence/NN
of/IN
the/DT
promoter/NN
sequence/NN
of/IN
human/JJ
glucose/NN
transporter/NN
type/NN
2/CD
(/(
GLUT2/NN
)/)
./.
====================
The/DT
luciferase/NN
reporter/NN
assay/NN
revealed/VBD
that/IN
P159L/NN
HNF1B/NN
had/VBD
decreased/VBN
transcriptional/JJ
activity/NN
compared/VBN
to/TO
wild-type/JJ
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
showed/VBD
reduced/VBN
DNA/NN
binding/NN
activity/NN
of/IN
P159L/NN
HNF1B/NN
./.
====================
In/IN
the/DT
MIN6/NN
pancreatic/JJ
β-cell/NN
line/NN
,/,
overexpression/NN
of/IN
the/DT
P159L/NN
mutant/JJ
was/VBD
significantly/RB
associated/VBN
with/IN
decreased/VBN
mRNA/NN
levels/NNS
of/IN
GLUT2/NN
compared/VBN
to/TO
wild-type/JJ
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
However/RB
,/,
INS/NN
expression/NN
was/VBD
not/RB
different/JJ
between/IN
the/DT
wild-type/JJ
and/CC
mutant/JJ
HNF1B/NN
constructs/NNS
./.
====================
These/DT
findings/NNS
suggests/VBZ
that/IN
the/DT
impaired/JJ
insulin/NN
secretion/NN
in/IN
this/DT
family/NN
with/IN
the/DT
P159L/NN
HNF1B/NN
mutation/NN
may/MD
be/VB
related/JJ
to/TO
altered/JJ
GLUT2/NN
expression/NN
in/IN
β-cells/NNS
rather/RB
than/IN
decreased/VBN
insulin/NN
gene/NN
expression/NN
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
have/VBP
identified/VBN
a/DT
Korean/JJ
family/NN
with/IN
an/DT
HNF1B/NN
mutation/NN
and/CC
characterized/VBN
its/PRP$
effect/NN
on/IN
the/DT
pathogenesis/NN
of/IN
diabetes/NNS
./.
====================
Maturity-onset/NN
diabetes/NNS
of/IN
the/DT
young/JJ
(/(
MODY/NN
)/)
is/VBZ
a/DT
monogenic/JJ
form/VBP
of/IN
diabetes/NNS
characterized/VBN
by/IN
an/DT
early/JJ
onset/NN
,/,
usually/RB
before/IN
the/DT
age/NN
of/IN
25/CD
years/NNS
;/:
an/DT
autosomal/JJ
dominant/JJ
inheritance/IN
;/:
and/CC
a/DT
defect/NN
in/IN
pancreatic/JJ
β-cell/NN
function/NN
[/(
1/CD
]/)
./.
====================
Depending/VBG
on/IN
the/DT
specific/JJ
gene/NN
mutation/NN
,/,
the/DT
synthesis/NN
and/CC
secretion/NN
of/IN
insulin/NN
are/VBP
altered/JJ
at/IN
different/JJ
stages/NNS
./.
====================
MODY/NN
is/VBZ
classified/VBN
according/VBG
to/TO
its/PRP$
affected/VBN
genes/NNS
,/,
which/WDT
include/VBP
those/DT
encoding/VBG
enzymes/NNS
,/,
transcription/NN
factors/NNS
,/,
and/CC
other/JJ
types/NNS
of/IN
proteins/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
The/DT
transcription/NN
factors/NNS
associated/VBN
with/IN
MODY/NN
act/VBP
in/IN
the/DT
nucleus/NN
of/IN
β-cells/NNS
and/CC
regulate/VBP
the/DT
transcription/NN
of/IN
INS/NN
or/CC
other/JJ
genes/NNS
encoding/VBG
enzymes/NNS
involved/VBN
in/IN
glucose/NN
transport/VBP
and/CC
metabolism/NN
[/(
1/CD
]/)
./.
====================
Hepatocyte/NN
nuclear/JJ
factor-1β/NN
(/(
HNF-1β/NN
)/)
is/VBZ
a/DT
homeodomain-containing/JJ
transcription/NN
factor/NN
that/WDT
forms/VBZ
a/DT
homodimer/NN
or/CC
heterodimer/NN
with/IN
structurally/RB
related/JJ
HNF-1α/NN
[/(
3/CD
]/)
./.
====================
HNF1B/NN
has/VBZ
9/CD
exons/NNS
and/CC
encodes/VBZ
a/DT
557-amino-acid/JJ
peptide/NN
./.
====================
Its/PRP$
structure/NN
is/VBZ
characterized/VBN
by/IN
a/DT
highly/RB
conserved/VBN
DNA-binding/JJ
domain/NN
composed/VBN
of/IN
an/DT
atypical/JJ
POU-specific/JJ
(/(
POUS/NNS
)/)
and/CC
POU-homeo/JJ
(/(
POUH/NN
)/)
domain/NN
,/,
but/CC
the/DT
molecular/JJ
properties/NNS
of/IN
HNF-1β/NN
have/VBP
not/RB
been/VBN
studied/VBN
much/RB
./.
====================
HNF-1/NN
β/RB
is/VBZ
known/VBN
for/IN
playing/VBG
a/DT
role/NN
in/IN
tissue-specific/JJ
gene/NN
expression/NN
in/IN
organs/NNS
,/,
including/VBG
the/DT
liver/NN
,/,
kidney/NN
,/,
and/CC
pancreatic/JJ
islets/NNS
[/(
4/CD
]/)
,/,
and/CC
is/VBZ
involved/VBN
in/IN
the/DT
β-cell/JJ
transcription/NN
factor/NN
network/NN
[/(
5/CD
]/)
./.
====================
Heterozygous/JJ
mutations/NNS
of/IN
HNF1B/NN
,/,
which/WDT
encodes/VBZ
HNF-1β/NN
,/,
result/NN
in/IN
maturity-onset/NN
diabetes/VBZ
of/IN
the/DT
young/JJ
5/CD
(/(
MODY5/NN
)/)
,/,
which/WDT
is/VBZ
characterized/VBN
by/IN
early-onset/JJ
diabetes/VBZ
and/CC
various/JJ
abnormalities/NNS
,/,
such/JJ
as/IN
renal/JJ
cysts/NNS
,/,
renal/JJ
impairment/NN
,/,
genital/JJ
malformation/NN
,/,
or/CC
hepatobiliary/JJ
involvement/NN
[/(
6/CD
,/,
7/CD
,/,
8/CD
,/,
9/CD
]/)
./.
====================
Patients/NNS
with/IN
mutations/NNS
in/IN
HNF1B/NN
have/VBP
impaired/JJ
insulin/NN
secretory/JJ
responses/NNS
to/TO
glucose/NN
and/CC
insulin/NN
secretagogues/NNS
[/(
7/CD
,/,
10/CD
,/,
11/CD
]/)
and/CC
show/VBP
progressive/JJ
loss/NN
in/IN
basal/JJ
insulin/NN
secretion/NN
./.
====================
Mutation/NN
in/IN
HNF1B/NN
was/VBD
first/JJ
described/VBN
by/IN
Horikawa/NN
et/FW
al/JJ
./.
====================
in/IN
1997/CD
[/(
12/CD
]/)
./.
====================
Different/JJ
mutation/NN
types/NNS
,/,
including/VBG
missense/NN
,/,
nonsense/JJ
,/,
and/CC
frameshift/NN
mutations/NNS
,/,
have/VBP
been/VBN
found/VBN
in/IN
different/JJ
domains/NNS
[/(
13/CD
,/,
14/CD
,/,
15/CD
]/)
./.
====================
Recently/RB
,/,
mutations/NNS
in/IN
exon/NN
2/CD
and/CC
in/IN
the/DT
DNA-binding/JJ
domain/NN
have/VBP
been/VBN
reported/VBN
[/(
16/CD
,/,
17/CD
,/,
18/CD
,/,
19/CD
,/,
20/CD
]/)
./.
====================
Barbacci/NNS
et/FW
al/JJ
./.
====================
[/(
21/CD
]/)
characterized/VBN
eight/CD
naturally/RB
occurring/VBG
mutations/NNS
in/IN
different/JJ
domains/NNS
./.
====================
Truncated/VBN
mutations/NNS
showed/VBD
defective/JJ
nuclear/JJ
localization/NN
and/CC
weak/JJ
dominant-negative/JJ
activity/NN
,/,
whereas/IN
a/DT
frameshift/NN
mutation/NN
within/IN
the/DT
QSP-rich/JJ
domain/NN
had/VBD
partially/RB
reduced/VBD
transcriptional/JJ
activity/NN
./.
====================
Missense/NN
mutations/NNS
in/IN
POUS/NN
and/CC
POUH/NN
exhibited/VBD
severe/JJ
decreases/NNS
in/IN
transcription/NN
./.
====================
A/DT
certain/JJ
mutation/NN
showed/VBD
a/DT
gain-of-function/NN
phenotype/NN
[/(
22/CD
,/,
23/CD
]/)
./.
====================
In/IN
vitro/FW
studies/NNS
suggested/VBD
that/IN
clinical/JJ
phenotypes/NNS
may/MD
be/VB
related/JJ
to/TO
loss/NN
of/IN
function/NN
and/or/CC
dominant-negative/JJ
mechanisms/NNS
[/(
8/CD
,/,
24/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
identified/VBN
a/DT
family/NN
with/IN
MODY5/NN
harboring/VBG
a/DT
heterozygous/JJ
P159L/NN
HNF1B/NN
mutation/NN
./.
====================
We/PRP
evaluated/VBD
the/DT
functional/JJ
consequences/NNS
of/IN
this/DT
HNF1B/NN
mutation/NN
on/IN
glucose/NN
metabolism/NN
./.
====================
Sequencing/NN
of/IN
HNF1B/NN
====================
The/DT
HNF1B/NN
of/IN
the/DT
patient/NN
was/VBD
sequenced/VBN
by/IN
Sanger/NN
method/NN
in/IN
peripheral/JJ
blood/NN
DNA/NN
./.
====================
Her/RB
father/JJ
,/,
mother/NN
,/,
and/CC
younger/JJR
brother/JJR
were/VBD
also/RB
screened/VBN
by/IN
the/DT
same/JJ
method/NN
./.
====================
Written/RB
informed/VBN
consent/NN
for/IN
the/DT
genetic/JJ
study/NN
was/VBD
obtained/VBN
from/IN
the/DT
patient/NN
and/CC
her/RB
family/NN
members/NNS
before/IN
sequencing/NN
./.
====================
Wild-type/JJ
and/CC
mutant/JJ
plasmid/NN
constructs/NNS
====================
Human/JJ
wild-type/JJ
HNF1B/NN
,/,
cloned/VBN
in/IN
pCMV6b/NN
,/,
was/VBD
provided/VBN
by/IN
Dr./NNP
J./NNP
Takeda/NN
,/,
Gifu/NNP
University/NN
,/,
Japan/NNP
./.
====================
A/DT
point/NN
mutation/NN
was/VBD
generated/VBN
by/IN
PCR-based/JJ
site-directed/JJ
mutagenesis/NN
using/VBG
the/DT
QuickChange/NN
Mutagenesis/NN
Kit/NN
(/(
Stratagene/NN
,/,
La/NN
Jolla/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
The/DT
promoter/NN
of/IN
human/JJ
glucose/NN
transporter/NN
type/NN
2/CD
(/(
GLUT2/NN
)/)
(/(
-1296/CD
to/TO
+312/CD
)/)
,/,
cloned/VBN
in/IN
the/DT
pGL3-Basic/JJ
vector/NN
(/(
Promega/NN
,/,
Madison/NN
,/,
WI/NN
,/,
USA/NNP
)/)
,/,
was/VBD
provided/VBN
by/IN
Dr./NNP
M.S/NNS
./.
====================
Lee/NNP
,/,
Sungkyunkwan/JJ
University/NN
,/,
Korea/NN
./.
====================
The/DT
sequences/NNS
of/IN
all/DT
genes/NNS
for/IN
the/DT
experiment/NN
were/VBD
confirmed/VBN
by/IN
direct/JJ
nucleotide/NN
sequencing/NN
./.
====================
Cell/NN
culture/NN
====================
COS-7/NN
cells/NNS
were/VBD
maintained/VBN
in/IN
Dulbecco/NN
's/POS
modified/VBN
Eagle/JJ
's/POS
medium/NN
(/(
DMEM/NN
)/)
with/IN
10/CD
%/NN
fetal/JJ
bovine/NN
serum/NN
(/(
Invitrogen/NN
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
supplemented/VBN
with/IN
100/CD
U/mL/NN
of/IN
penicillin/NN
and/CC
100/CD
µg/mL/NN
of/IN
streptomycin/NN
,/,
before/IN
transient/JJ
transfection/NN
./.
====================
MIN6/NN
cells/NNS
were/VBD
cultured/VBN
in/IN
RPMI/NN
1640/CD
with/IN
11.1/CD
mM/NN
D-glucose/NN
supplemented/VBN
with/IN
10/CD
%/NN
fetal/JJ
bovine/NN
serum/NN
(/(
Invitrogen/NN
)/)
and/CC
the/DT
same/JJ
antibiotics/NNS
as/IN
for/IN
COS-7/NN
./.
====================
Cells/NNS
were/VBD
cultured/VBN
at/IN
37℃/CD
in/IN
5/CD
%/NN
CO2:95/NN
%/NN
air/NN
./.
====================
Transient/JJ
transfection/NN
====================
COS-7/NN
cells/NNS
were/VBD
subcultured/VBN
in/IN
12-well/NN
plates/VBZ
the/DT
day/NN
before/IN
transfection/NN
;/:
0.2/CD
µg/NN
of/IN
pGL3-GLUT2/NN
promoter/NN
,/,
0.02/CD
µg/VBG
of/IN
HNF1B/NN
expression/NN
plasmids/NNS
,/,
and/CC
0.05/CD
µg/VBG
of/IN
pCMV-β-galactosidase/NN
were/VBD
combined/VBN
with/IN
LipofectAMINE/NN
PLUS/NN
agent/NN
(/(
Invitrogen/NN
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocol/NN
./.
====================
The/DT
cells/NNS
,/,
in/IN
400/CD
µL/NN
of/IN
serum-free/JJ
DMEM/NN
,/,
were/VBD
treated/VBN
with/IN
the/DT
complex/NN
for/IN
3/CD
h/NN
,/,
and/CC
the/DT
medium/NN
was/VBD
changed/VBN
to/TO
DMEM/NN
with/IN
10/CD
%/NN
fetal/JJ
bovine/NN
serum/NN
./.
====================
MIN6/NN
cells/NNS
were/VBD
subcultured/VBN
in/IN
6-well/JJ
plates/VBZ
the/DT
day/NN
before/IN
transfection/NN
./.
====================
As/IN
it/PRP
is/VBZ
difficult/JJ
to/TO
transfect/VB
genes/NNS
into/IN
MIN6/NN
cells/NNS
,/,
the/DT
transfection/NN
efficiency/NN
was/VBD
evaluated/VBN
with/IN
the/DT
green/VBN
fluorescent/JJ
protein/NN
gene/NN
(/(
GFP/NN
)/)
first/JJ
./.
====================
After/IN
the/DT
efficiency/NN
was/VBD
confirmed/VBN
,/,
0.5/CD
µg/NN
of/IN
expression/NN
vector/NN
for/IN
HNF1B/NN
per/FW
well/RB
was/VBD
administered/VBN
./.
====================
Serum-containing/VBG
medium/NN
was/VBD
added/VBN
up/IN
to/TO
the/DT
normal/JJ
volume/NN
after/IN
3/CD
h/NN
of/IN
incubation/NN
and/CC
replaced/VBD
with/IN
fresh/JJ
complete/JJ
RPMI/NN
1640/CD
after/IN
8/CD
h./RB
MIN6/NN
cells/NNS
were/VBD
harvested/VBN
for/IN
RNA/NN
extraction/NN
and/CC
protein/NN
quantitation/NN
after/IN
30/CD
h/NN
after/IN
the/DT
start/NN
of/IN
transfection/NN
./.
====================
Luciferase/NN
reporter/NN
assays/NNS
====================
Twenty-four/CD
hours/NNS
after/IN
the/DT
start/NN
of/IN
transfection/NN
,/,
Cos7/NN
cells/NNS
were/VBD
lysed/VBN
with/IN
reporter/NN
lysis/NN
buffer/NN
and/CC
harvested/VBD
,/,
and/CC
the/DT
transcriptional/JJ
activity/NN
was/VBD
measured/VBN
using/VBG
the/DT
Luciferase/NN
assay/NN
system/NN
(/(
Promega/NNP
)/)
and/CC
Lumet/NN
LB9507/NN
(/(
Berthold/JJ
,/,
Bad/NN
Wildbad/JJ
,/,
Germany/NNP
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
To/TO
normalize/VB
transfection/NN
efficiency/NN
,/,
β-galactosidase/NN
activity/NN
was/VBD
measured/VBN
./.
====================
Ten/CD
microliters/NNS
of/IN
cell/NN
lysate/NN
was/VBD
mixed/VBN
with/IN
3/CD
µL/NN
of/IN
100/CD
×/NN
MgCl2/NN
(/(
0.1/CD
M/NN
MgCl2/NN
and/CC
4.5/CD
M/NN
β-mercaptoethanol/NN
)/)
and/CC
66/CD
µL/NN
1/CD
×/NN
o-nitrophenyl-β-D-galactoside/NN
./.
====================
The/DT
activity/NN
of/IN
β-galactosidase/NN
was/VBD
measured/VBN
by/IN
VersaMax/NN
spectrophotometry/NN
at/IN
420/CD
nm/NN
(/(
Molecular/JJ
devices/VBZ
,/,
Sunnyvale/JJ
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
====================
Double-stranded/JJ
oligonucleotides/NNS
composed/VBN
of/IN
the/DT
following/VBG
sequences/NNS
were/VBD
used/VBN
for/IN
human/JJ
GLUT2/NN
promoter/NN
probes/NNS
:/:
5'-AAG/JJ
ACC/NN
TCA/NN
GTA/NN
AAG/NN
ATT/NN
AAC/NN
CAT/NN
CAT/NN
TA-3/NN
'/``
;/:
1/LS
µg/IN
of/IN
up/RB
and/CC
down/RB
sequences/NNS
of/IN
single-stranded/JJ
oligomer/JJ
were/VBD
hybridized/VBN
within/IN
PE/NN
buffer/CC
(/(
20/CD
mM/NN
Tris/NNP
,/,
10/CD
mM/NN
MgCl2/NN
,/,
50/CD
nM/NN
NaCl/NN
,/,
1/CD
mM/NN
dithiothreitol/NN
[/(
DTT/NN
]/)
)/)
by/IN
incubating/VBG
them/PRP
at/IN
72℃/CD
for/IN
10/CD
min/NN
and/CC
then/RB
at/IN
room/JJ
temperature/NN
for/IN
15/CD
min/NN
./.
====================
The/DT
probe/NN
was/VBD
labeled/VBN
with/IN
[/(
α-32P/RB
]/)
dATP/NN
by/IN
Klenow/JJ
DNA/NN
polymerase/NN
(/(
Ambion/NNP
,/,
Austin/NNP
,/,
TX/NNP
,/,
USA/NNP
)/)
,/,
and/CC
the/DT
labeled/JJ
probe/NN
(/(
25,000/CD
cpm/RB
)/)
was/VBD
incubated/VBN
with/IN
nuclear/JJ
extracts/NNS
of/IN
COS-7/NN
cells/NNS
that/IN
were/VBD
transfected/VBN
with/IN
pcDNA/JJ
,/,
wild-type/JJ
HNF1B/NN
,/,
and/CC
H153N/JJ
and/CC
P159L/NN
HNF1B/NN
in/IN
10/CD
mM/NN
HEPES/NN
(/(
pH/NN
7.9/CD
,/,
Sigma-Aldrich/JJ
,/,
St./NNP
Louis/NNP
,/,
MO/NNP
,/,
USA/NNP
)/)
containing/VBG
50/CD
mM/NN
KCl/NNP
,/,
0.1/CD
mM/NN
EDTA/NN
,/,
0.25/CD
mM/NN
DTT/NN
,/,
0.1/CD
mg/mL/NN
poly/RB
(/(
dIdC/RB
)/)
,/,
0.01/CD
%/NN
Nonidet/JJ
P-40/NN
,/,
and/CC
10/CD
%/NN
glycerol/NN
at/IN
room/JJ
temperature/NN
./.
====================
DNA-protein/JJ
complexes/NNS
were/VBD
separated/VBN
on/IN
6/CD
%/NN
polyacrylamide/NN
gels/NNS
and/CC
detected/VBN
by/IN
autoradiography/NN
./.
====================
RNA/NN
isolation/NN
and/CC
real-time/VBP
PCR/NN
====================
Mutant/JJ
or/CC
wild-type/JJ
HNF1B/NN
was/VBD
overexpressed/VBN
in/IN
the/DT
mouse/NN
pancreatic/JJ
β-cell/NN
line/NN
MIN6/NN
./.
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
using/VBG
TRIzol/NN
(/(
Invitrogen/NN
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
To/TO
prepare/VB
cDNA/NN
,/,
6/CD
µL/NN
of/IN
reaction/NN
buffer/NN
(/(
Invitrogen/NN
)/)
,/,
3/CD
µL/NN
of/IN
100/CD
mM/NN
DTT/NN
,/,
1.5/CD
µL/NN
of/IN
10/CD
mM/NN
dNTP/NN
,/,
0.6/CD
µL/NN
of/IN
random/JJ
primer/NN
,/,
0.3/CD
µL/NN
of/IN
RNase/NN
inhibitor/NN
,/,
1.0/CD
µL/NNS
of/IN
RTase/NN
,/,
and/CC
1/CD
µg/NN
of/IN
RNA/NN
were/VBD
mixed/VBN
,/,
and/CC
RNase-free/JJ
water/NN
was/VBD
added/VBN
up/IN
to/TO
30/CD
µL/NN
./.
====================
The/DT
mixture/NN
was/VBD
incubated/VBN
37℃/CD
for/IN
1/CD
h/NN
and/CC
72℃/CD
for/IN
10/CD
min/NN
using/VBG
a/DT
PCR/NN
system/NN
./.
====================
Expression/NN
levels/NNS
of/IN
genes/NNS
were/VBD
determined/VBN
by/IN
using/VBG
SYBR/NN
Master/NN
Mix/NN
(/(
Takara/NN
,/,
Otsu/NNP
,/,
Japan/NNP
)/)
and/CC
an/DT
AB/LS
7500/CD
Real-time/NN
PCR/NN
system/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
primer/NN
sequences/NNS
for/IN
the/DT
PCR/NN
were/VBD
as/IN
follows/VBZ
:/:
5'-GGC/JJ
TAA/NN
TTT/NN
CAG/NN
GAC/NN
TGG/NN
TT-3/NN
'/``
and/CC
5'-TTT/JJ
CTT/NN
TGC/NN
CCT/NN
GAC/NN
TTC/NN
CT-3/NN
'/``
for/IN
GLUT2/NN
and/CC
5'-CTC/NN
GGC/NN
TCA/NN
CCG/NN
TTT/NN
CCT/NN
T-3/NN
'/``
and/CC
5'-CGC/JJ
GCT/NN
TGC/NN
TAA/NN
TAG/NN
TGC/NN
AG-3/NN
'/``
for/IN
INS/NN
./.
====================
Samples/NNS
were/VBD
prepared/VBN
repetitively/RB
,/,
and/CC
each/DT
sample/NN
was/VBD
analyzed/VBN
in/IN
duplicate/JJ
./.
====================
Expression/NN
levels/NNS
of/IN
each/DT
gene/NN
were/VBD
measured/VBN
relative/JJ
to/TO
18S/NN
and/CC
normalized/VBD
to/TO
the/DT
expression/NN
levels/NNS
in/IN
total/JJ
RNA/NN
with/IN
the/DT
ΔΔCT/NN
method/NN
./.
====================
Western/NN
blot/NN
analysis/NN
====================
Cells/NNS
were/VBD
lysed/VBN
in/IN
a/DT
buffer/NN
containing/VBG
20/CD
mM/NN
Tris-HCl/NN
,/,
pH/NN
7.4/CD
,/,
5/CD
mM/NN
Na4P2O7/NN
,/,
100/CD
nM/NN
NaF/NN
,/,
2/CD
mM/NN
Na3VO4/NN
,/,
1/CD
%/NN
NP-40/CD
,/,
and/CC
protease/NN
inhibitor/NN
(/(
1/CD
µg/µL/NN
of/IN
aprotinin/NN
,/,
1/CD
µg/µL/NN
of/IN
leupeptin/NN
,/,
and/CC
1/CD
mM/NN
of/IN
PMSF/NN
;/:
Sigma-Aldrich/JJ
)/)
./.
====================
After/IN
determination/NN
of/IN
protein/NN
concentrations/NNS
,/,
equal/JJ
amounts/NNS
of/IN
cell/NN
lysates/NNS
were/VBD
separated/VBN
by/IN
sodium/NN
dodecyl/NN
sulfate/NN
polyacrylamide/NN
gel/NN
electrophoresis/NN
./.
====================
Separated/JJ
proteins/NNS
were/VBD
transferred/VBN
onto/IN
a/DT
nitrocellulose/JJ
membrane/NN
(/(
Whatman/NNP
,/,
Dassel/NN
,/,
Germany/NNP
)/)
./.
====================
The/DT
membrane/NN
was/VBD
blocked/VBN
with/IN
5/CD
%/NN
skim/NN
milk/NN
in/IN
Tris-buffered/JJ
saline-Tween-20/NN
(/(
TBS-T/NN
)/)
for/IN
1/CD
h/NN
at/IN
room/JJ
temperature/NN
and/CC
incubated/VBN
with/IN
rabbit/NN
polyclonal/JJ
anti-HNF-1β/JJ
antibody/NN
(/(
Santa/NN
Cruz/NN
Biotech/NNP
,/,
San/NNP
Diego/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
at/IN
4℃/CD
./.
====================
After/IN
8/CD
h/NN
,/,
the/DT
membranes/NNS
were/VBD
probed/VBN
with/IN
secondary/JJ
antibody/NN
,/,
and/CC
bands/NNS
were/VBD
visualized/VBN
by/IN
enhanced/VBN
chemi-luminescence/NN
(/(
Pierce/NN
,/,
Rockford/NNP
,/,
IL/NN
,/,
USA/NN
)/)
./.
====================
Statistical/JJ
analysis/NN
====================
Data/NNS
were/VBD
expressed/VBN
as/IN
mean/JJ
±/CD
standard/JJ
error/NN
(/(
SE/NN
)/)
./.
====================
The/DT
non-parametric/JJ
t-test/JJS
and/CC
one-way/NN
ANOVA/NN
were/VBD
used/VBN
to/TO
compare/VB
the/DT
mean/JJ
values/NNS
between/IN
the/DT
groups/NNS
with/IN
GraphPad/JJ
Prism/NN
version/NN
5.0/CD
(/(
GraphPad/JJ
Software/JJ
,/,
Inc./NNP
,/,
La/NN
Jolla/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
p/NN
</JJR
0.05/CD
was/VBD
considered/VBN
statistically/RB
significant/JJ
./.
====================
All/DT
individual/JJ
experiments/NNS
were/VBD
performed/VBN
at/IN
least/JJS
in/IN
duplicate/JJ
and/CC
were/VBD
repeated/VBN
five/CD
times/NNS
on/IN
separate/JJ
occasions/NNS
./.
====================
A/DT
27-year-old/JJ
woman/NN
with/IN
inadequately/RB
controlled/VBN
diabetes/VBZ
mellitus/NN
was/VBD
admitted/VBN
for/IN
glycemic/JJ
control/NN
./.
====================
She/PRP
was/VBD
diagnosed/VBN
as/IN
having/VBG
diabetes/NNS
mellitus/NN
at/IN
an/DT
age/NN
of/IN
14/CD
(/(
fasting/VBG
plasma/NN
glucose/NN
137/CD
mg/dL/NN
,/,
postprandial/JJ
2-h/JJ
glucose/NN
239/CD
mg/dL/NN
)/)
,/,
with/IN
normal/JJ
body/NN
mass/NN
index/NN
(/(
21.9/CD
kg/m2/NN
)/)
and/CC
24-h/JJ
urine/NN
C-peptide/NN
level/NN
(/(
83.3/CD
µg/day/JJ
;/:
reference/RB
range/NN
,/,
50/CD
to/TO
100µg/day/JJ
)/)
./.
====================
Although/IN
autoantibodies/NNS
for/IN
pancreatic/JJ
β-cell/NN
were/VBD
not/RB
detected/VBN
,/,
she/PRP
required/VBD
insulin/NN
therapy/NN
for/IN
glycemic/JJ
control/NN
./.
====================
Her/RB
serum/NN
C-peptide/NN
level/NN
decreased/VBD
from/IN
1.8/CD
ng/mL/NN
to/TO
0.9/CD
ng/mL/NN
during/IN
the/DT
past/NN
year/NN
./.
====================
The/DT
total/JJ
daily/RB
insulin/NN
requirement/NN
was/VBD
0.68/CD
IU/kg/NN
./.
====================
The/DT
patient/NN
's/POS
father/JJ
(/(
diagnosed/VBN
in/IN
his/DT
early/JJ
30s/NNS
)/)
and/CC
grandmother/JJ
(/(
the/DT
age/NN
of/IN
diagnosis/NN
was/VBD
unknown/JJ
)/)
also/RB
had/VBD
diabetes/NNS
./.
====================
She/PRP
did/VBD
not/RB
have/VB
urogenital/JJ
anomalies/NNS
./.
====================
Sequencing/NN
of/IN
HNF1B/NN
revealed/VBD
a/DT
heterozygous/JJ
P159L/NN
point/NN
mutation/NN
(/(
CCT/NN
to/TO
CTT/NN
in/IN
codon/NN
159/CD
)/)
in/IN
the/DT
patient/NN
./.
====================
Among/IN
the/DT
three/CD
other/JJ
family/NN
members/NNS
,/,
her/RB
father/JJ
was/VBD
found/VBN
to/TO
have/VB
the/DT
identical/JJ
mutation/NN
./.
====================
The/DT
pedigree/JJ
of/IN
diabetes/NNS
mellitus/NN
and/CC
the/DT
result/NN
of/IN
Sanger/NN
sequencing/NN
are/VBP
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
This/DT
nonsynonymous/JJ
variant/JJ
co-segregated/VBN
according/VBG
to/TO
the/DT
affected/VBN
state/NN
of/IN
diabetes/NNS
within/IN
the/DT
family/NN
./.
====================
Two/CD
point/NN
mutations/NNS
,/,
P159L/NN
and/CC
H153N/NN
(/(
for/IN
comparison/NN
as/IN
functionally/RB
proven/VBN
mutations/NNS
;/:
i.e./FW
,/,
positive/JJ
control/NN
)/)
,/,
were/VBD
generated/VBN
by/IN
in/FW
vitro/FW
mutagenesis/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Western/NN
blot/NN
analysis/NN
confirmed/VBD
that/IN
the/DT
mutant/JJ
protein/NN
was/VBD
apparently/RB
expressed/VBN
in/IN
the/DT
transfected/VBN
COS-7/NN
cells/NNS
(/(
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
The/DT
region/NN
,/,
including/VBG
nucleotide/NN
-1030/CD
of/IN
human/JJ
GLUT2/NN
promoter/NN
,/,
which/WDT
is/VBZ
known/VBN
to/TO
be/VB
the/DT
cis-element/JJ
for/IN
HNF-1β/NN
binding/VBG
[/(
24/CD
]/)
,/,
was/VBD
inserted/VBN
into/IN
the/DT
luciferase/NN
vector/NN
(/(
Fig/NN
./.
====================
3B/NN
)/)
./.
====================
Luciferase/NN
activity/NN
of/IN
the/DT
human/JJ
GLUT2/NN
promoter/NN
was/VBD
increased/VBN
with/IN
overexpression/NN
of/IN
wild-type/JJ
HNF-1β/NN
compared/VBN
to/TO
the/DT
control/NN
(/(
p/NN
</JJR
0.05/CD
vs./CC
control/NN
)/)
(/(
Fig/NN
./.
====================
3C/NN
)/)
./.
====================
When/WRB
P159L/NN
HNF-1β/NN
and/CC
H153N/NN
HNF-1β/NN
were/VBD
expressed/VBN
,/,
a/DT
significant/JJ
reduction/NN
of/IN
transcription/NN
activity/NN
was/VBD
observed/VBN
(/(
p/NN
</JJR
0.05/CD
vs./CC
wild-type/JJ
,/,
respectively/RB
)/)
./.
====================
In/IN
the/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
(/(
EMSA/NN
)/)
,/,
the/DT
proteins/NNS
of/IN
the/DT
expected/VBN
sizes/NNS
were/VBD
translated/VBN
(/(
Fig/NN
./.
====================
4A/CD
)/)
./.
====================
The/DT
EMSA/NN
showed/VBD
that/IN
wild-type/JJ
HNF-1β/NN
protein/NN
bound/VBD
well/RB
to/TO
the/DT
GLUT2/NN
promoter/NN
,/,
but/CC
the/DT
mutant/JJ
proteins/NNS
had/VBD
decreased/VBN
binding/NN
activity/NN
(/(
Fig/NN
./.
====================
4B/NN
)/)
./.
====================
The/DT
mRNA/NN
levels/NNS
of/IN
GLUT2/NN
and/CC
INS/NN
in/IN
MIN6/NN
cells/NNS
after/IN
HNF1B/NN
transfection/NN
were/VBD
also/RB
investigated/VBD
./.
====================
The/DT
transfection/NN
into/IN
MIN6/NN
was/VBD
confirmed/VBN
with/IN
an/DT
efficiency/NN
of/IN
60/CD
%/NN
to/TO
65/CD
%/NN
(/(
Fig/NN
./.
====================
5A/CD
)/)
./.
====================
Western/NN
blot/NN
analysis/NN
showed/VBD
that/IN
the/DT
protein/NN
expression/NN
was/VBD
well/RB
preserved/VBN
after/IN
transfection/NN
(/(
Fig/NN
./.
====================
5B/NN
)/)
./.
====================
The/DT
quantitated/VBN
mRNA/NN
levels/NNS
were/VBD
normalized/VBN
to/TO
that/DT
of/IN
18S/NN
./.
====================
When/WRB
the/DT
wild-type/JJ
HNF-1β/NN
was/VBD
overexpressed/VBN
,/,
the/DT
relative/JJ
mRNA/NN
level/NN
of/IN
GLUT2/NN
was/VBD
increased/VBN
by/IN
2.3-fold/JJ
(/(
p/NN
</JJR
0.05/CD
vs./CC
control/NN
)/)
(/(
Fig/NN
./.
====================
5C/NN
)/)
./.
====================
Compared/VBN
to/TO
the/DT
wild-type/JJ
HNF-1β/NN
,/,
the/DT
relative/JJ
mRNA/NN
levels/NNS
of/IN
GLUT2/NN
for/IN
the/DT
H153N/NN
and/CC
P159L/NN
mutants/NNS
were/VBD
significantly/RB
decreased/VBD
(/(
p/NN
</JJR
0.05/CD
vs./CC
wild-type/JJ
,/,
respectively/RB
)/)
./.
====================
There/EX
was/VBD
no/DT
significant/JJ
difference/NN
in/IN
the/DT
mRNA/NN
expression/NN
level/NN
of/IN
INS/NN
among/IN
the/DT
four/CD
groups/NNS
(/(
Fig/NN
./.
====================
5D/CD
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
identified/VBD
a/DT
MODY5/NN
family/NN
with/IN
a/DT
nonsynonymous/JJ
mutation/NN
in/IN
the/DT
HNF1B/NN
gene/NN
./.
====================
The/DT
patient/NN
was/VBD
suspected/VBN
to/TO
have/VB
MODY/NN
,/,
especially/RB
MODY5/NN
,/,
because/IN
of/IN
the/DT
lack/NN
of/IN
response/NN
to/TO
sulfonylureas/NNS
,/,
early/JJ
(/(
within/IN
3/CD
years/NNS
)/)
requirement/NN
of/IN
exogenous/JJ
insulin/NN
,/,
and/CC
features/NNS
of/IN
insulin/NN
resistance/NN
[/(
25/CD
]/)
./.
====================
Although/IN
the/DT
patient/NN
did/VBD
not/RB
have/VB
specific/JJ
clinical/JJ
features/NNS
of/IN
HNF1B/NN
mutation/NN
,/,
such/JJ
as/IN
cystic/JJ
kidney/NN
disease/NN
[/(
6/CD
]/)
,/,
she/PRP
had/VBD
fulfilled/JJ
the/DT
clinical/JJ
diagnostic/JJ
criteria/NNS
of/IN
MODY/NN
./.
====================
The/DT
clinical/JJ
features/NNS
of/IN
MODY5/NN
vary/VBP
as/IN
either/CC
diabetes/NNS
or/CC
urinary/JJ
tract/NN
malformation/NN
,/,
or/CC
both/CC
could/MD
be/VB
the/DT
presenting/VBG
symptoms/NNS
[/(
14/CD
,/,
20/CD
,/,
26/CD
]/)
./.
====================
According/VBG
to/TO
a/DT
systematic/JJ
review/NN
performed/VBN
by/IN
Chen/NNP
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
,/,
renal/JJ
structural/JJ
anomalies/NNS
are/VBP
relatively/RB
less/RBR
frequent/JJ
in/IN
missense/NN
mutations/NNS
than/IN
in/IN
other/JJ
types/NNS
of/IN
mutation/NN
./.
====================
On/IN
the/DT
contrary/NN
,/,
the/DT
percentage/NN
of/IN
diabetes/NNS
mellitus/NN
and/CC
the/DT
frequency/NN
of/IN
insulin/NN
treatment/NN
tended/VBD
to/TO
be/VB
higher/JJR
./.
====================
The/DT
mutation/NN
of/IN
P159L/NN
was/VBD
heterozygous/JJ
c.476C/NN
>/JJR
T/NN
in/IN
exon/NN
2/CD
of/IN
HNF1B/NN
,/,
which/WDT
is/VBZ
in/IN
the/DT
DNA-binding/JJ
domain/NN
./.
====================
Chen/NNP
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
found/VBN
that/IN
mutations/NNS
in/IN
HNF1B/NN
were/VBD
more/RBR
likely/JJ
to/TO
be/VB
located/JJ
in/IN
the/DT
DNA-binding/JJ
domain/NN
,/,
and/CC
the/DT
hotspots/NNS
were/VBD
in/IN
exons/NNS
2/CD
and/CC
4/CD
./.
====================
Yamagata/NNS
[/(
28/CD
]/)
reviewed/VBD
that/DT
N228K/NN
is/VBZ
a/DT
relatively/RB
common/JJ
polymorphism/NN
in/IN
Pima/NN
Indians/NNS
,/,
and/CC
the/DT
A241T/NN
,/,
G492S/NN
,/,
and/CC
S465R/NN
mutations/NNS
might/MD
be/VB
rare/JJ
polymorphisms/NNS
./.
====================
In/IN
HNF1B-deficient/JJ
mouse/NN
embryos/NNS
,/,
a/DT
dorsal/JJ
bud/VBP
of/IN
the/DT
pancreas/NN
is/VBZ
formed/VBN
transiently/RB
and/CC
becomes/VBZ
absent/JJ
,/,
whereas/IN
the/DT
ventral/JJ
bud/VBP
is/VBZ
not/RB
affected/VBN
[/(
29/CD
]/)
./.
====================
In/IN
two/CD
8-week/JJ
human/JJ
fetuses/NNS
with/IN
HNF1B/NN
mutations/NNS
,/,
severe/JJ
pancreas/NN
hypoplasia/NN
was/VBD
observed/VBN
[/(
30/CD
]/)
./.
====================
With/IN
these/DT
consistent/JJ
findings/NNS
,/,
the/DT
abnormality/NN
in/IN
the/DT
morphogenesis/NN
of/IN
the/DT
pancreas/NN
is/VBZ
thought/VBN
to/TO
be/VB
one/CD
of/IN
the/DT
causes/VBZ
of/IN
diabetes/NNS
in/IN
MODY5/NN
patients/NNS
./.
====================
Another/DT
suggested/VBD
molecular/JJ
mechanism/NN
is/VBZ
related/JJ
to/TO
altered/JJ
GLUT2/NN
expression/NN
./.
====================
Wild-type/JJ
HNF-1β/NN
is/VBZ
known/VBN
to/TO
bind/VB
to/TO
the/DT
cis-element/JJ
of/IN
GLUT2/NN
and/CC
efficiently/RB
increase/VBP
its/PRP$
transcription/NN
[/(
24/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
overexpression/NN
of/IN
wild-type/JJ
HNF-1β/NN
resulted/VBD
in/IN
an/DT
increase/NN
in/IN
transcriptional/JJ
activity/NN
of/IN
the/DT
GLUT2/NN
promoter/NN
,/,
whereas/IN
overexpression/NN
of/IN
the/DT
P159L/NN
mutant/JJ
resulted/VBD
in/IN
decreased/VBN
GLUT2/NN
expression/NN
./.
====================
Previous/JJ
studies/NNS
showed/VBD
similar/JJ
results/NNS
in/IN
various/JJ
types/NNS
of/IN
cells/NNS
,/,
such/JJ
as/IN
COS-7/NN
,/,
MIN6/NN
,/,
and/CC
HepG2/NN
[/(
20/CD
,/,
24/CD
]/)
./.
====================
GLUT2/NN
is/VBZ
a/DT
low-affinity/JJ
,/,
high-capacity/JJ
transporter/NN
expressed/VBN
mainly/RB
in/IN
hepatocytes/NNS
,/,
renal/JJ
proximal/JJ
tubule/NN
cells/NNS
,/,
and/CC
pancreatic/JJ
β-cells/NNS
[/(
31/CD
,/,
32/CD
]/)
./.
====================
GLUT2/NN
plays/VBZ
a/DT
role/NN
in/IN
β-cell/JJ
insulin/NN
secretion/NN
,/,
as/IN
it/PRP
senses/VBZ
external/JJ
glucose/NN
and/CC
transports/VBZ
it/PRP
into/IN
pancreatic/JJ
β-cells/NNS
[/(
33/CD
]/)
./.
====================
In/IN
vivo/FW
studies/NNS
showed/VBD
that/IN
GLUT2-deficient/JJ
mice/NNS
were/VBD
hyperglycemic/JJ
,/,
resulting/VBG
in/IN
diabetes/NNS
with/IN
impaired/JJ
glucose/NN
sensing/VBG
by/IN
pancreatic/JJ
β-cells/NNS
[/(
34/CD
]/)
,/,
and/CC
GLUT2/NN
was/VBD
undetectable/JJ
on/IN
β-cells/NNS
of/IN
the/DT
two/CD
HNF1B/NN
mutant/JJ
fetuses/NNS
[/(
29/CD
]/)
./.
====================
So/RB
,/,
decreased/VBD
expression/NN
of/IN
GLUT2/NN
in/IN
β-cells/NNS
,/,
combined/JJ
with/IN
a/DT
gradual/JJ
reduction/NN
in/IN
insulin/NN
secretion/NN
,/,
could/MD
be/VB
involved/VBN
in/IN
the/DT
pathogenesis/NN
of/IN
diabetes/NNS
mellitus/NN
in/IN
MODY5/NN
patients/NNS
./.
====================
In/IN
addition/NN
,/,
GLUT2/NN
may/MD
also/RB
affect/VB
β-cell/JJ
differentiation/NN
in/IN
the/DT
development/NN
of/IN
the/DT
pancreas/NN
[/(
34/CD
,/,
35/CD
]/)
./.
====================
EMSA/NN
was/VBD
done/VBN
to/TO
examine/VB
whether/IN
the/DT
reduced/VBN
transcription/NN
activity/NN
was/VBD
due/JJ
to/TO
the/DT
decreased/VBN
DNA-binding/JJ
capacity/NN
./.
====================
Both/DT
mutant/JJ
HNF-1β/NN
proteins/NNS
had/VBD
decreased/VBN
DNA-binding/JJ
activity/NN
compared/VBN
to/TO
the/DT
wild-type/JJ
./.
====================
It/PRP
was/VBD
previously/RB
reported/VBD
that/IN
the/DT
H153N/NN
HNF-1β/NN
mutation/NN
had/VBD
diminished/VBN
DNA-binding/JJ
activity/NN
[/(
20/CD
]/)
./.
====================
Since/IN
both/CC
P159L/NN
and/CC
H153N/NN
mutants/NNS
have/VBP
intact/JJ
dimerization/NN
domains/NNS
,/,
it/PRP
is/VBZ
possible/JJ
that/IN
they/PRP
could/MD
dimerize/VB
with/IN
wild-type/JJ
HNF-1β/NN
[/(
9/CD
]/)
./.
====================
However/RB
,/,
the/DT
mutant/wild-type/JJ
dimer/NN
seems/VBZ
to/TO
have/VB
a/DT
defect/NN
in/IN
DNA/NN
binding/NN
and/CC
limited/JJ
ability/NN
to/TO
increase/VB
the/DT
transcription/NN
of/IN
GLUT2/NN
./.
====================
The/DT
mRNA/NN
expression/NN
of/IN
GLUT2/NN
was/VBD
increased/VBN
with/IN
wild-type/JJ
HNF-1β/NN
but/CC
significantly/RB
suppressed/VBD
,/,
almost/RB
to/TO
the/DT
level/NN
observed/VBN
in/IN
the/DT
empty/JJ
control/NN
vector/NN
,/,
in/IN
both/DT
mutants/NNS
./.
====================
The/DT
findings/NNS
of/IN
the/DT
real-time/NN
PCR/NN
analysis/NN
of/IN
GLUT2/NN
were/VBD
consistent/JJ
with/IN
the/DT
reporter/NN
gene/NN
assay/NN
and/CC
DNA/NN
binding/NN
assay/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
there/EX
has/VBZ
been/VBN
limited/VBN
knowledge/NN
regarding/VBG
the/DT
mRNA/NN
expression/NN
of/IN
INS/NN
with/IN
mutant/JJ
HNF-1β/NN
./.
====================
The/DT
mRNA/NN
levels/NNS
of/IN
INS/NN
were/VBD
not/RB
statistically/RB
different/JJ
between/IN
the/DT
wild-type-/JJ
and/CC
mutant-expressing/JJ
MIN6/NN
cells/NNS
./.
====================
In/IN
one/CD
study/NN
with/IN
HNF-1α/NN
,/,
neither/CC
the/DT
wild-type/JJ
nor/CC
the/DT
mutant/JJ
activated/VBN
GLUT2/NN
or/CC
the/DT
insulin/NN
promoter/NN
in/IN
MIN6/NN
cells/NNS
[/(
36/CD
]/)
./.
====================
The/DT
authors/NNS
concluded/VBD
that/IN
endogenous/JJ
HNF-1α/NN
,/,
GLUT2/NN
,/,
and/CC
insulin/NN
proteins/NNS
in/IN
MIN6/NN
cells/NNS
could/MD
interfere/VB
in/IN
the/DT
transfected/VBN
reporter/NN
assay/NN
./.
====================
The/DT
mRNA/NN
expression/NN
of/IN
INS/NN
is/VBZ
also/RB
considered/VBN
to/TO
be/VB
regulated/VBN
by/IN
other/JJ
transcription/NN
factors/NNS
,/,
and/CC
it/PRP
might/MD
have/VBP
been/VBN
compensated/VBN
for/IN
by/IN
complex/NN
mechanisms/NNS
against/IN
the/DT
mutation/NN
of/IN
HNF1B/NN
./.
====================
Overall/RB
,/,
the/DT
impaired/JJ
insulin/NN
secretion/NN
in/IN
MODY5/NN
patients/NNS
might/MD
be/VB
explained/VBN
by/IN
pancreatic/JJ
hypoplasia/NN
or/CC
β-cell/JJ
dysgenesis/NN
rather/RB
than/IN
decreased/VBN
mRNA/NN
expression/NN
of/IN
INS/NN
./.
====================
As/IN
described/VBN
above/IN
,/,
decreased/VBD
mRNA/NN
expression/NN
of/IN
GLUT2/NN
might/MD
also/RB
result/VBP
in/IN
the/DT
inhibition/NN
of/IN
insulin/NN
secretion/NN
./.
====================
This/DT
study/NN
has/VBZ
some/DT
limitations/NNS
./.
====================
First/RB
,/,
we/PRP
could/MD
not/RB
sequence/NN
HNF1B/NN
of/IN
the/DT
patient/NN
's/POS
grandmother/JJ
,/,
who/WP
was/VBD
also/RB
a/DT
patient/NN
with/IN
diabetes/NNS
./.
====================
If/IN
she/PRP
had/VBD
the/DT
same/JJ
P159L/NN
mutation/NN
of/IN
HNF1B/NN
,/,
it/PRP
would/MD
have/VBP
revealed/VBN
an/DT
autosomal/JJ
dominant/JJ
inheritance/NN
more/RBR
clearly/RB
./.
====================
Second/RB
,/,
alterations/NNS
in/IN
insulin/NN
secretion/NN
with/IN
the/DT
mutation/NN
in/IN
the/DT
pancreatic/JJ
β-cell/NN
line/NN
were/VBD
not/RB
evaluated/VBN
./.
====================
Further/RB
studies/NNS
of/IN
functional/JJ
changes/NNS
in/IN
the/DT
P159L/NN
mutation/NN
are/VBP
needed/VBN
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
have/VBP
identified/VBN
a/DT
P159L/NN
mutation/NN
of/IN
HNF1B/NN
in/IN
a/DT
family/NN
with/IN
MODY5/NN
and/CC
have/VBP
characterized/VBN
the/DT
functional/JJ
consequences/NNS
of/IN
this/DT
nonsynonymous/JJ
mutation/NN
in/IN
the/DT
pathogenesis/NN
of/IN
diabetes/NNS
./.
====================
This/DT
mutation/NN
revealed/VBD
decreased/VBD
DNA-binding/JJ
activity/NN
and/CC
decreased/VBD
transcriptional/JJ
activity/NN
of/IN
GLUT2/NN
./.
====================
The/DT
mRNA/NN
expression/NN
of/IN
GLUT2/NN
in/IN
pancreatic/JJ
β-cell/NN
lines/NNS
was/VBD
also/RB
significantly/RB
decreased/VBD
with/IN
this/DT
mutation/NN
,/,
whereas/IN
that/DT
of/IN
INS/NN
was/VBD
not/RB
altered/JJ
./.
====================
Impaired/JJ
insulin/NN
secretion/NN
in/IN
the/DT
patient/NN
with/IN
the/DT
P159L/NN
mutation/NN
in/IN
HNF1B/NN
might/MD
be/VB
associated/VBN
with/IN
the/DT
alteration/NN
of/IN
GLUT2-related/JJ
signaling/NN
pathways/NNS
./.
====================
The/DT
pedigree/JJ
of/IN
diabetes/NNS
mellitus/NN
in/IN
the/DT
case/NN
family/NN
and/CC
the/DT
result/NN
of/IN
HNF1B/NN
sequencing/NN
./.
====================
(/(
A/NN
)/)
The/DT
patient/NN
's/POS
father/JJ
and/CC
grandmother/JJ
were/VBD
affected/VBN
by/IN
diabetes/NNS
mellitus/NN
./.
====================
(/(
B/NN
)/)
Sanger/NNP
sequencing/NN
of/IN
HNF1B/NN
was/VBD
done/VBN
with/IN
blood/NN
samples/NNS
of/IN
the/DT
patient/NN
and/CC
her/RB
family/NN
members/NNS
(/(
parents/NNS
and/CC
a/DT
younger/RBR
brother/RBR
)/)
,/,
which/WDT
revealed/VBD
the/DT
same/JJ
heterozygous/JJ
P159L/NN
(/(
CCT/NN
to/TO
CTT/NN
)/)
mutation/NN
in/IN
the/DT
patient/NN
and/CC
her/RB
affected/VBN
father/RB
./.
====================
The/DT
sites/NNS
of/IN
mutation/NN
and/CC
the/DT
oligonucleotides/NNS
used/VBD
for/IN
in/IN
vitro/FW
mutagenesis/NN
of/IN
HNF1B/NN
./.
====================
(/(
A/NN
)/)
Upper/IN
bar/JJ
shows/VBZ
the/DT
structure/NN
of/IN
wild-type/JJ
human/JJ
HNF-1β/NN
./.
====================
It/PRP
consists/VBZ
of/IN
a/DT
dimerization/NN
domain/NN
(/(
a.a./FW
1-32/CD
)/)
,/,
DNA-binding/JJ
domain/NN
(/(
a.a./FW
106-310/CD
)/)
,/,
and/CC
transactivation/NN
domain/NN
(/(
a.a./FW
310-557/CD
)/)
./.
====================
The/DT
P159L/NN
(/(
c.476C/NN
>/JJR
T/NN
)/)
mutation/NN
and/CC
the/DT
H153N/NN
mutation/NN
(/(
c.457C/NN
>/JJR
A/NN
)/)
were/VBD
generated/VBN
as/IN
lower/JJR
bars/VBZ
./.
====================
The/DT
H153N/JJ
mutant/JJ
was/VBD
a/DT
functionally/RB
proven/VBN
mutation/NN
./.
====================
(/(
B/NN
)/)
The/DT
oligonucleotides/NNS
used/VBD
for/IN
mutagenesis/NN
are/VBP
shown/VBN
./.
====================
WT/NN
,/,
wild-type/JJ
;/:
POUS/NNS
,/,
POU-specific/JJ
;/:
POUH/NN
,/,
POU-homeo/JJ
;/:
HNF-1β/NN
,/,
hepatocyte/NN
nuclear/JJ
factor-1β/NN
./.
====================
Transcriptional/JJ
activity/NN
of/IN
the/DT
wild-type/JJ
and/CC
mutant/JJ
HNF-1β/NN
./.
====================
The/DT
WT/NN
and/CC
mutant/JJ
(/(
H153N/NN
,/,
P159L/NN
)/)
HNF1B/NN
expression/NN
plasmids/NNS
(/(
0.02/CD
µg/VBG
)/)
were/VBD
transfected/VBN
into/IN
COS-7/NN
cells/NNS
with/IN
0.2/CD
µg/NN
of/IN
pGL3-hGLUT2/NN
promoter/NN
./.
====================
β-Galactosidase/DT
activity/NN
was/VBD
used/VBN
for/IN
normalization/NN
of/IN
transfection/NN
efficiency/NN
./.
====================
(/(
A/NN
)/)
HNF-1β/NN
proteins/NNS
expressed/VBN
by/IN
Western/NN
blot/NN
./.
====================
(/(
B/NN
)/)
Human/JJ
GLUT2/NN
promoter/NN
regions/NNS
inserted/VBN
into/IN
the/DT
luciferase/NN
vector/NN
./.
====================
(/(
C/NN
)/)
The/DT
relative/JJ
luciferase/NN
activity/NN
was/VBD
measured/VBN
./.
====================
Fold-induction/NN
refers/VBZ
to/TO
the/DT
activity/NN
with/IN
vehicle/NN
./.
====================
Result/NN
is/VBZ
represented/VBN
as/IN
means/NNS
±/CD
SE/NN
of/IN
five/CD
independent/JJ
experiments/NNS
./.
====================
veh/RB
,/,
vehicle/NN
;/:
WT/NN
,/,
wild-type/JJ
;/:
HNF-1β/NN
,/,
hepatocyte/NN
nuclear/JJ
factor-1β/NN
;/:
GLUT2/NN
,/,
glucose/NN
transporter/NN
type/NN
2/CD
./.
====================
*p/RB
</JJR
0.05/CD
./.
====================
DNA-binding/JJ
activity/NN
of/IN
the/DT
wild-type/JJ
and/CC
HNF-1β/NN
mutants/NNS
./.
====================
Electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
(/(
EMSA/NN
)/)
was/VBD
done/VBN
with/IN
oligonucleotide/NN
probes/NNS
of/IN
the/DT
human/JJ
GLUT2/NN
promoter/NN
:/:
5'-AAG/NN
ACC/NN
TCA/NN
GTA/NN
AAG/NN
ATT/NN
AAC/NN
CAT/NN
CAT/NN
TA-3/NN
'/``
./.
====================
The/DT
probe/NN
was/VBD
incubated/VBN
with/IN
nuclear/JJ
extracts/NNS
of/IN
COS-7/NN
cells/NNS
transfected/VBN
with/IN
pcDNA/JJ
,/,
wild-type/JJ
,/,
and/CC
two/CD
HNF1B/NN
mutants/NNS
./.
====================
(/(
A/NN
)/)
The/DT
proteins/NNS
of/IN
HNF-1β/NN
were/VBD
detected/VBN
by/IN
Western/NN
blot/NN
./.
====================
(/(
B/NN
)/)
EMSA/NN
shows/VBZ
that/IN
wild-type/JJ
HNF-1β/NN
is/VBZ
binding/VBG
to/TO
the/DT
GLUT2/NN
promoter/NN
,/,
but/CC
mutants/NNS
are/VBP
not/RB
./.
====================
WT/NN
,/,
wild-type/JJ
;/:
FP/NN
,/,
fluorescence/NN
polarization/NN
;/:
GAPDH/NN
,/,
glyceraldehyde/NN
3-phosphate/JJ
dehydrogenase/NN
;/:
HNF-1β/NN
,/,
hepatocyte/NN
nuclear/JJ
factor-1β/NN
;/:
GLUT2/NN
,/,
glucose/NN
transporter/NN
type/NN
2/CD
./.
====================
Effects/NNS
of/IN
mutant/JJ
HNF-1β/NN
on/IN
the/DT
mRNA/NN
levels/NNS
of/IN
GLUT2/NN
and/CC
INS/NN
in/IN
MIN6/NN
./.
====================
MIN6/NN
cells/NNS
were/VBD
transfected/VBN
with/IN
wild-type/JJ
or/CC
mutant/JJ
HNF-1β/NN
./.
====================
Thirty/DT
hours/NNS
after/IN
the/DT
transfection/NN
,/,
cells/NNS
were/VBD
harvested/VBN
and/CC
prepared/VBN
for/IN
quantitative/JJ
PCR/NN
analysis/NN
./.
====================
Isolated/JJ
RNAs/NNS
were/VBD
quantitated/VBN
by/IN
real-time/NN
PCR/NN
using/VBG
specific/JJ
primers/NNS
for/IN
GLUT2/NN
and/CC
INS/NN
./.
====================
The/DT
mRNA/NN
level/NN
of/IN
each/DT
gene/NN
was/VBD
normalized/VBN
by/IN
18S/NN
./.
====================
(/(
A/NN
)/)
The/DT
transfection/NN
efficiency/NN
was/VBD
about/RB
60/CD
%/NN
-65/CD
%/NN
,/,
measured/VBN
by/IN
GFP/NN
transfection/NN
in/IN
MIN6/NN
cells/NNS
./.
====================
(/(
B/NN
)/)
The/DT
wild-type/JJ
and/CC
mutant/JJ
HNF-1β/NN
proteins/NNS
were/VBD
expressed/VBN
well/RB
by/IN
Western/NN
blot/NN
./.
====================
GLUT2/NN
(/(
C/NN
)/)
and/CC
INS/NN
mRNA/NN
(/(
D/NN
)/)
levels/NNS
are/VBP
represented/VBN
as/IN
means/NNS
±/CD
SE/NN
of/IN
five/CD
independent/JJ
experiments/NNS
./.
====================
veh/RB
,/,
vehicle/NN
;/:
WT/NN
,/,
wild-type/JJ
;/:
HNF-1β/NN
,/,
hepatocyte/NN
nuclear/JJ
factor-1β/NN
;/:
GLUT2/NN
,/,
glucose/NN
transporter/NN
type/NN
2/CD
;/:
GFP/NN
,/,
green/VBN
fluorescent/JJ
protein/NN
./.
====================
*p/RB
</JJR
0.05/CD
./.
====================
